Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel

Background HER2-positive advanced breast cancer (ABC) is associated with significant heterogeneity in long-term disease control and survival. Prognostic models for HER2-positive ABC patients considering first-line pertuzumab, trastuzumab and docetaxel have not been evaluated. Methods A pre-treatment prognostic model for progression-free survival (PFS) and overall survival (OS) was developed for HER2-positive ABC patients initiating first-line pertuzumab, trastuzumab and docetaxel using clinicopathological data from the randomised clinical trial CLEOPATRA (n=408). Cox proportional hazard analysis with a backwards deletion process was used. Results Metastatic sites count ( ULN) were identified as common pre-treatment risk predictors for PFS and OS (P
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research